导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -0.18% | 2217/4345 |
| 近一周 | -2.01% | 2927/4962 |
| 近一月 | -4.46% | 2937/4922 |
| 近一季 | -6.43% | 2208/4747 |
| 近半年 | -1.97% | 1789/4477 |
| 近一年 | 4.07% | 1741/4016 |
| 近两年 | 50.10% | 1351/2712 |
| 近三年 | 32.82% | 878/2054 |
| 成立以来 | 39.62% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-3.02% 3005/4961 |
13.40% 2011/5312 |
- - |
- - |
| 2025 | 23.10% 1906/4813 |
0.28% 1919/3635 |
1.21% 2420/4076 |
20.65% 1940/4524 |
0.53% 1953/4813 |
| 2024 | 16.65% 783/3463 |
2.79% 698/2808 |
-0.75% 831/3014 |
16.70% 1380/3129 |
-2.02% 1929/3463 |
| 2023 | -9.59% 1197/2656 |
4.61% 911/2280 |
-4.46% 1178/2385 |
-2.96% 808/2515 |
-6.78% 1915/2655 |
| 2022 | -20.47% 973/2207 |
-13.15% 704/1919 |
6.21% 750/2016 |
-14.59% 1119/2113 |
0.96% 1420/2208 |
| 2021 | -6.63% 1014/1822 |
-2.12% 585/1255 |
1.08% 1068/1330 |
-7.02% 1014/1466 |
1.50% 900/1822 |
| 2020 | 33.19% 462/1250 |
-10.08% 748/1028 |
12.07% 701/1067 |
14.74% 258/1164 |
15.18% 228/1184 |
| 2019 | - - |
- - |
- - |
0.31% 532/850 |
5.77% 679/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 广发中证A100ETF联接A VS. 长安沪深300非周期A(740101) |